29–31 Aug orders dispatch 1 SeptRegistered Pharmacy100% OnlineFully Inspected & Regulated ServicesApproved UK-licensed Treatments29–31 Aug orders dispatch 1 SeptRegistered Pharmacy100% OnlineFully Inspected & Regulated ServicesApproved UK-licensed Treatments
13 Jun 2026
8min read
Contents
At the time of this update, Wegovy® tablets have been approved by the MHRA in the UK for weight loss and weight management. This comparison is based on published trial data, the approved Wegovy tablet, and the licensed Mounjaro injection. We will update this page when Lyv availability, pricing and any final product details are confirmed.
UK adults considering a private weight-loss medication now face a clearer three-way decision: the Wegovy injection, the Wegovy pill, and Mounjaro® (tirzepatide). The Wegovy injection versus Mounjaro comparison is covered in Lyv’s dedicated Mounjaro vs Wegovy guide. This page focuses on the newer comparison: the Wegovy pill versus Mounjaro.
These two medicines are not subtle differences of the same thing. They use different mechanisms, different molecules, different delivery methods and different dosing routines. Below is the short answer, then the detail.
For wider treatment context, visit Lyv’s weight-loss treatment page.
Mounjaro is, on current trial evidence, one of the most effective single weight-loss medicines available in the UK on average. The Wegovy pill produces meaningful weight loss with oral semaglutide, but trial averages suggest tirzepatide produces larger average weight loss than oral semaglutide.
Mounjaro is an injection, taken once weekly. The Wegovy pill is oral, taken once daily, with strict dosing rules. The pill has no injection and may suit patients who would not adhere to an injection routine.
Both medicines affect GLP-1 pathways and work largely through appetite reduction. Both share a gastrointestinal side-effect profile, with nausea, diarrhoea, constipation and abdominal discomfort most common during dose escalation.
If maximum average weight loss is the priority and injection is acceptable, Mounjaro may be the better fit. If avoiding injection is the priority and the empty-stomach dosing rules are workable, the Wegovy pill may be the better fit. There is no universal answer.
Semaglutide, the active ingredient in Wegovy, is a GLP-1 receptor agonist. It binds to the GLP-1 receptor and produces effects including reduced appetite, slower gastric emptying, and increased insulin response after meals.
Tirzepatide, the active ingredient in Mounjaro, is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 receptor and the GIP receptor. GIP, or glucose-dependent insulinotropic polypeptide, is another incretin hormone with overlapping but distinct effects on insulin secretion, appetite and metabolism.
The combined activity appears to produce greater average weight loss than GLP-1 agonism alone in clinical trials. Whether the GIP contribution is mainly appetite-related, metabolism-related or a combination is still being studied, but the two molecules are mechanistically different in a way that matters for outcomes.
For more on how oral semaglutide works, read Lyv’s guide to how the Wegovy pill works.
This is the most visible difference for most patients.
Mounjaro is a once-weekly injection using a KwikPen. The Wegovy pill is a once-daily tablet taken on an empty stomach with strict dosing rules. It should be taken with a small amount of water, before food, other drinks or other oral medication, according to the official product information and prescriber instructions.
The injection trades a weekly needle for a more flexible schedule. The pill trades the needle for a rigid daily routine that must be followed consistently to maintain absorption.
The practical question is: which routine are you more likely to actually follow? A poorly adhered-to medicine, regardless of which is theoretically more effective, will under-deliver.
For a deeper practical comparison, read Lyv’s guide to Wegovy pill vs injection in the UK.
Mounjaro’s pivotal SURMOUNT-1 trial found substantial average weight loss at 72 weeks across the 5 mg, 10 mg and 15 mg tirzepatide doses. The highest dose produced the largest average reduction, with around 20% or more mean body-weight reduction reported in the trial.
Oral semaglutide’s OASIS-4 trial studied once-daily oral semaglutide 25 mg over 64 weeks in adults with overweight or obesity. The trial showed greater mean weight loss with oral semaglutide than with placebo.
The Wegovy injection’s STEP-1 trial reported approximately 14.9% mean weight loss at 68 weeks in adults with obesity or overweight, compared with 2.4% with placebo.
Three things matter when comparing these numbers.
First, the trials are not head-to-head. Different populations, durations and protocols mean direct numerical comparison can overstate the precision of the difference.
Second, individual responses vary widely. A trial-average difference does not mean every patient on Mounjaro loses more than every patient on oral semaglutide. There is overlap between response patterns.
Third, real-world weight loss can be lower than trial averages because of imperfect adherence, side effects, life events and the gap between trial conditions and daily life. This effect may matter more for the pill because of the stricter dosing rules.
The honest summary: Mounjaro produces larger mean weight loss in trials. Whether this translates to a meaningful real-world difference for any individual patient depends on adherence, tolerability and personal response. It is not a guarantee.
Both medicines affect GLP-1 pathways and share a dominant side-effect profile: nausea, vomiting, diarrhoea, constipation and abdominal discomfort, especially during dose escalation.
Mounjaro’s dual GIP/GLP-1 mechanism can produce a slightly different tolerability pattern, although direct head-to-head data against oral semaglutide in obesity is limited. Some patients tolerate one better than the other; the pattern is individual and not predictable in advance.
The Wegovy pill has the empty-stomach absorption issue described in the mechanism article. Failing to follow the dosing rules can reduce efficacy and may worsen gastrointestinal symptoms. Mounjaro has no equivalent empty-stomach dosing requirement.
Class effects — pancreatitis, gallbladder problems, thyroid C-cell tumour warnings and hypoglycaemia risk when combined with some diabetes medicines — should be considered for both medicines during clinical assessment.
For more detail, read Lyv’s guides to Wegovy pill side effects and Mounjaro side effects in the UK.
Mounjaro: once weekly, by subcutaneous injection. It is usually started at a low starter dose and increased gradually under clinical supervision, according to the licensed dosing schedule and patient tolerability.
Wegovy pill: once daily, by mouth. The dose is stepped up according to the official product information and prescriber instructions. The empty-stomach dosing protocol is central to how the medicine is absorbed.
Both medicines require clinical assessment before treatment and review during dose escalation. Neither is a “fire-and-forget” regimen.
Mounjaro pricing varies by provider, dose and supply route. Wegovy pill pricing will depend on manufacturer supply, pharmacy pricing and clinical service setup.
Once pricing is confirmed, Lyv will update this page with a clear per-month comparison where possible.
For current Lyv treatment pricing, visit our transparent pricing page.
Price is rarely the only factor that should drive the choice between these medicines. Tolerability, clinical suitability and adherence usually matter more.
Mounjaro may suit you better if:
The Wegovy pill may suit you better if:
Either may suit you if:
Neither is a poor choice when clinically appropriate. The wrong choice is the one you will not take consistently or safely.
Wegovy and Mounjaro are prescription-only medicines. The decision to prescribe is made by an independent UK-registered prescriber after a clinical assessment.
This article is general information for UK adults and is not a substitute for personalised medical advice. Prescription-only medicines mentioned are supplied only after a clinician-led consultation through a regulated pharmacy. If you have urgent symptoms or concerns about a medicine, speak to your GP, pharmacist, NHS 111 or emergency services as appropriate.
